PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare announced today that the U.S. Food and Drug Administration (FDA) has designated for priority review the New Drug Application (NDA) for AdreView. AdreView is a molecular imaging agent for the detection of neuroendocrine tumors in pediatric and adult patients. The FDA also encouraged GE to establish an expanded access program for the agent. An expanded access program is designed to grant physicians limited access to a novel agent prior to FDA approval.
